You chose a platform, trained your team, and built your workflows around it. Then, midway through a running study or at the start of a new one, you realise you cannot easily leave. Data migration is too complex, support has slowed down, prices have increased, and evaluating an alternative feels like a project in itself. Vendor lock-in in clinical research is not a theoretical risk. It is a situation that many sponsors, CROs, and academic research centres recognise once they are too far into a contract to exit without significant cost.

In this blog, we explain how vendor lock-in develops in research software, which warning signs to recognise early, and what you can do to protect your organisation’s long-term flexibility.

Vendor lock-in means your organisation is so dependent on a single software supplier that switching carries disproportionate cost, time, or risk. In clinical research, the consequences are higher than in most other sectors. Study integrity, regulatory compliance, and patient safety are at stake.

Dependency rarely develops in a single moment. It is a series of small decisions compounding over time: a platform that stores data in a proprietary format, a contract with automatic renewals and opaque exit clauses, training that is system-specific rather than process-oriented, or an implementation so deeply embedded in your workflows that switching feels like starting from scratch.

Clinical research is also long-duration by nature. A Phase III study can run four to seven years. Software that meets your needs at the start may not do so halfway through. By then, the exit is far more complex than it would have been at the outset.

Data access and export options are restricted
You cannot export your data in an open, standardised format (such as CDISC-compliant outputs), or export is only available as a paid service provided by the vendor itself.

Prices increase at renewal without transparent justification
If you have no benchmark and cannot evaluate an alternative without significant effort, your vendor’s negotiating position is considerably stronger than yours.

Integrations are closed or carry additional costs
An EDC that does not connect openly to a CTMS or an eTMF forces more manual work or requires purchasing additional modules from the same supplier.

Training is system-specific rather than skills-based
When staff learn only how to operate one system rather than how the underlying processes work, institutional knowledge becomes embedded in the platform rather than in your organisation.

The warning signs above are recognisable, but they are also avoidable. At ResearchManager, you are not tied to long-term contracts that lock you into a platform: we offer short-term contract options, so you can evaluate at any time whether the arrangement still fits your organisation’s needs. The Clinical Research Suite is built on a modular architecture, with modules deployable individually or in combination, and if you no longer wish to use a particular module, a full migration export is always available. Switching is not a blocked path, but a genuine option.

The same applies on the technical side. Closed integrations and restricted data export are precisely where dependency takes hold; that is why the suite connects to existing and other systems via an open API, and all data can be exported in universal formats such as Excel and CSV. For us, continuity means more than uptime and support: we actively involve our customers in the development of the platform, so that it grows alongside the organisations using it rather than remaining a static product they eventually outgrow.

One of the most effective ways to avoid vendor lock-in is to choose a modular platform. Modular design means you adopt only the tools you need, and that individual tools can be replaced without having to rebuild the entire environment.

The Clinical Research Suite from ResearchManager is built on this principle. Tools including EDC, CTMS, eTMF, RIMS, eConsent, and ePRO can be deployed individually or in combination. Organisations can begin with a single module and expand as their needs grow.

The choice of research software is also a choice about how dependent you are willing to become. Vendor lock-in in clinical research is avoidable, but it requires preparation. It starts with the right questions, transparent contracts, and a supplier that not only meets your needs today but continues to do so tomorrow, and that involves its customers in how the platform evolves.

Want to know how we approach this in practice? Speak with one of our experts.